Skip to main content

Advertisement

Table 2 Correlations between baseline parameters and the reduction of body weight or HbA1c at 1 year

From: Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study

Baseline parameters Reduction of body weight Reduction of HbA1c
  Univariate Multivariate p value Univariate Multivariate p value
  r p value   r p value  
Age 0.006 0.955   −0.119 0.274  
Male −0.129 0.236   −0.137 0.209  
BMI 0.355 0.001 0.007 0.082 0.456  
WC 0.210 0.114   −0.078 0.563  
Duration of DM 0.087 0.447   −0.072 0.533  
SBP −0.158 0.146   0.002 0.986  
DBP −0.050 0.649   0.135 0.216  
FPG −0.066 0.549   −0.113 0.302  
HbA1c −0.114 0.295   0.564 <0.001 <0.001
LDL-C 0.014 0.897   0.203 0.066 0.693
TG −0.146 0.187   0.210 0.056 0.564
HDL-C −0.014 0.902   −0.087 0.432  
AST 0.224 0.049   −0.128 0.265  
ALT 0.230 0.035 0.091 0.111 0.313  
sCPR 0.010 0.934   0.054 0.662  
Insulin dose 0.266 0.016 0.461 −0.057 0.611  
Insulin dose U/kg 0.213 0.055   −0.061 0.583  
Eating behavior 0.247 0.256   0.066 0.765  
Previous treatment
Insulin 0.246 0.022 0.027 −0.225 0.037 0.374
BG −0.063 0.562   0.050 0.645  
SU −0.114 0.294   −0.046 0.284  
αGI −0.046 0.672   0.117 0.284  
TZD −0.072 0.503   0.054 0.622  
DPP4i 0.060 0.579   0.043 0.697  
Glinide −0.032 0.770   0.046 0.676  
  1. Reduction of body weight or HbA1c from baseline to 1 year was analyzed with baseline clinical parameters.
  2. BMI; body mass index, WC; waist circumference, DM; diabetes mellitus, SBP; systolic body pressure; DBP diastolic body pressure, FPG; fasting plasma glucose, HbA1c; glycated hemoglobin, LDL-C; low-density lipoprotein-cholesterol, TG; triglycerides, HDL-C; high-density lipoprotein-cholesterol, AST; aspartate aminotransferase, ALT; alanine aminotransferase, sCPR; serum C-peptide immunoreactivity, BG; biguanide, SU; Sulfonylurea, αGI; α-glucosidase inhibitor, TZD; thiazolidinedione, DPP4i; dipeptidyl peptidase-4 inhibitor.